Protective effects of triflusal on secondary thrombus growth and vascular cyclooxygenase-2

被引:5
作者
Duran, X. [1 ]
Sanchez, S. [1 ]
Vilahur, G. [1 ,2 ]
Badimon, L. [1 ,2 ,3 ]
机构
[1] Hosp Santa Creu & Sant Pau, CSIC ICCC, Cardiovasc Res Ctr, Barcelona 08025, Spain
[2] CIBEROBN Inst Salud Carlos III, Barcelona, Spain
[3] UAB, Cardiovasc Res Chair, Barcelona, Spain
关键词
cyclooxygenase inhibitors; prostacyclin; secondary thrombus;
D O I
10.1111/j.1538-7836.2008.03036.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Carotid residual mural thrombus predisposes to recurrent thrombosis and/or distal embolization (i.e. cerebrovascular ischemia). Objectives: Our aims were (i) to analyze and compare the efficacy of aspirin, triflusal, and its main metabolite 2-hydroxy-4-trifluorometylbenzoic acid (HTB) on secondary thrombus growth; and (ii) evaluate to what extent the three Cox-1 inhibitors influenced vascular Cox-1/Cox-2 expression and endothelial prostacyclin synthesis. Methods: In a rabbit model of ex vivo thrombosis, a fresh mural thrombus was formed on damaged vessels at flow conditions typical of mild and severe carotid stenoses. The effects of Cox-1 inhibitors administered both intravenously (i.v.) (aspirin 5 mg kg(-1), triflusal 10 mg kg(-1), and HTB 10 mg kg(-1)) and orally (p.o.) (8 days; aspirin 30 mg kg(-1) day(-1), and triflusal 40 mg kg(-1) day(-1)) on secondary thrombus growth were assessed by In-(111)deposited platelets and compared with a placebo control. Arterial Cox-1/Cox-2 expression after 8-day treatment was evaluated at mRNA and protein levels. Additionally, a drug-related dose-dependent in vitro assay was performed for endothelial PGI(2) release measurement (Cox-2 activity). Results: All Cox inhibitors similarly and significantly (P < 0.05) reduced secondary thrombus formation after i.v. and p.o. administration versus placebo control. Treatments exerted no effect on vascular Cox-1 mRNA whereas Cox-2 mRNA was moderately reduced by aspirin and triflusal (placebo 100% +/- 9%, aspirin 70% +/- 2% and triflusal 70% +/- 2%; P < 0.05). Cox-2 protein levels were slightly higher in the triflusal versus aspirin group (placebo 100% +/- 6%, aspirin 35% +/- 10% and triflusal 61% +/- 9%; P < 0.005 versus placebo). Interestingly, in vitro, HTB solely maintained endothelial PGI(2) synthesis levels similar to the control. Conclusions: At a similar level of efficacy in inhibiting secondary thrombosis, triflusal seems to better preserve Cox-2 expression than aspirin and its metabolite HTB was able to protect endothelial prostacyclin production.
引用
收藏
页码:1385 / 1392
页数:8
相关论文
共 37 条
[1]   Antithrombotic and thrombolytic therapy for ischemic stroke [J].
Albers, GW ;
Amarenco, P ;
Easton, JD ;
Sacco, RL ;
Teal, P .
CHEST, 2004, 126 (03) :483S-512S
[2]  
[Anonymous], 1988, LANCET, V2, P349
[3]  
[Anonymous], 2005, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004296.PUB2
[4]   Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques - Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions [J].
Badimon, JJ ;
Lettino, M ;
Toschi, V ;
Fuster, V ;
Berrozpe, M ;
Chesebro, JH ;
Badimon, L .
CIRCULATION, 1999, 99 (14) :1780-1787
[5]  
BADIMON L, 1987, J LAB CLIN MED, V110, P706
[7]   PLATELET THROMBUS FORMATION ON COLLAGEN TYPE-I - A MODEL OF DEEP VESSEL INJURY - INFLUENCE OF BLOOD RHEOLOGY, VONWILLEBRAND-FACTOR, AND BLOOD-COAGULATION [J].
BADIMON, L ;
BADIMON, JJ ;
TURITTO, VT ;
VALLABHAJOSULA, S ;
FUSTER, V .
CIRCULATION, 1988, 78 (06) :1431-1442
[8]  
Catella-Lawson Francesca, 2001, American Journal of Medicine, V110, p28S
[9]   Role of prostacyclin in the cardiovascular response to thromboxane A2 [J].
Cheng, Y ;
Austin, SC ;
Rocca, B ;
Koller, BH ;
Coffman, TM ;
Grosser, T ;
Lawson, JA ;
FitzGerald, GA .
SCIENCE, 2002, 296 (5567) :539-541
[10]   Antiplatelet drugs in the treatment of acute coronary syndromes:: Focus on cyclooxygenase inhibitors [J].
Cruz-Fernández, JM .
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2001, 3 (0I) :I23-I30